Helsinki Hospital Uses BNCT to Treat First Cancer PatientsNeutron Therapeutics LLC and Helsinki University Hospital have unveiled a groundbreaking milestone in treating cancer: the first patients in Europe have undergone accelerator-based boron...
BioMarin to Acquire Inozyme Pharma for USD 270 MillionBioMarin Pharmaceutical, Inc. has publicly disclosed a definitive agreement to acquire Inozyme Pharma, Inc in an all-cash transaction of nearly USD 270 million...
74th Indian Pharmaceutical Congress 2025 Opens RegistrationsThe Indian Pharmaceutical Congress, 2025 (IPC), which is organized by the Association of Pharmaceutical Teachers of India (APTI), has opened its registration...
Scientists at the National Institutes of Health (NIH) have found that alterations in the structure and cell composition of breast connective tissue, or stroma, are associated with a heightened risk for aggressive breast cancer in women with benign...
In an interaction with India Pharma Outlook, C. Mukundan, Managing Director, Atozeta Health Solutions, shared his valuable inputs on how AI-driven personalization and omnichannel scientific engagement are redefining pharma brand-building...
British pharmaceutical company GSK and iTeos Therapeutics announced on Tuesday that they had halted the development of belrestotug, an experimental treatment for lung cancer, after two tests showed that it was ineffective in halting the disease's pro
Johnson & Johnson announced compelling results from the phase 3 QUASAR long-term extension (LTE) study of Tremfya (guselkumab) in adults with moderately to severely active ulcerative colitis (UC). Presented at Digestive Disease Wee...
SCHOTT Pharma, a global leader in drug containment and delivery solutions, has announced a binding agreement with TPG, a prominent alternative asset management firm, under which TPG will acquire a...
IGI, a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ISB 2001.
Biocon Biologics has accomplished a major breakthrough in the U.S. with wide-ranging market access for Yesintek (ustekinumab-kfce), its biosimilar to Stelara, marking its first commercial launch in the country as a fully combined biosimilar company.
.jpg)
, CDSCO.jpg)